Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion type Assertion NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_head.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion description "[Interestingly, a potential gene fusion was also identified in amplified DDR2, which is a potential therapeutic target of kinase inhibitors such as dastinib, that are not routinely used in the treatment of patients with liposarcoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_provenance.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion evidence source_evidence_literature NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_provenance.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion SIO_000772 24505276 NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_provenance.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion wasDerivedFrom befree-20150227 NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_provenance.
- NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_assertion wasGeneratedBy ECO_0000203 NP600569.RAKOfVljHdV93e3jtIFWcy1r-Vp-c3KK0cmBmce9fComA130_provenance.